New drug bretisilocin tested in healthy volunteers for first time

NCT ID NCT07604558

Recruiting now Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a single dose of bretisilocin in 26 healthy adults from Japanese, Han Chinese, and Non-Asian backgrounds. Researchers are checking for side effects and how the drug moves through the body. The goal is to gather basic safety information before testing in people with a disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bretisilocin
What this could lead to: If successful, this study could provide early safety data to support future trials of bretisilocin for potential therapeutic uses.
What could go wrong: This is a very early Phase 1 trial with only 26 healthy volunteers, so results may not predict effects in patients. The drug could cause unexpected side effects or fail to show promise in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

CenExel Collaborative Neuroscience Research /ID# 281612
RECRUITING

Los Alamitos, California, 90720, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.